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We present a case of a Rendu-Osler-Weber disease patient with recurrent life threatening epistaxis demanding multiple blood
transfusions despite of repetitive endoscopic laser and electrocoagulations, endovascular embolisation, septodermoplasty, and
long-term intranasal dressings. As alternative treatment modalities repeatedly failed and the patient became almost permanently
dependent on nasal dressing, we performed a highly conformal intensity-modulated radiotherapy of the nasal cavity; a total dose
of 50Gy in 2Gy single fractions was applied. The therapy was very well tolerated, no acute toxicities occurred. Two weeks after
the last radiation dose had been applied, the nasal dressing could be removed without problems. Endoscopical control revealed an
almost avascular white mucosa without any trace of bleeding spots; previously existing hemangiomas and crusts had disappeared.
After a 1-year-follow up, the patient had no significant recurrent epistaxis.
1. Introduction
This study is a case report of a 69-year-old lady with
Rendu-Osler-Weber disease who regularly attended the ENT
outpatient ward of the Inselspital Bern because of recurrent
severe epistaxis.
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber disease is an autosomal dominant disorder
characterized by epistaxis, mucocutaneous telangiectases and
visceral arteriovenous malformations which aﬀects about 1
in 10,000 people [1]. There are hematologic, neurologic,
pulmonary, dermatologic and gastrointestinal complications
possible. Treatment is supportive and aims at preventing
complications [2]. A treatment guideline for epistaxis in
case of HHT recommends to do “as little as possible
for as long as possible” [3] whereas treatment modalities
include compression, topical antifibrinolitic therapy, laser
coagulations, embolisations [4] and as an ultima ratio
radiotherapy [5, 6].
2. Case Presentation
The 69-years-old lady presented in good performance and
nutritional status. Because of the HHT-related recurrent
severe epistaxis causing anemia she had undergone multiple
sessions of blood transfusions, laser or elctrocoagulations,
septal dermatoplastic interventions and transarterial emboli-
sations in the past.
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Figure 1: Radiotherapy planning I. IMRT plan with the planning target volume (PTV) in one CT cross section, red colours indicate a higher
dose; a steep dose gradient can be achieved by using fluence modulation with a multi leaf collimator. Normal tissues are optimally spared.
Additional medical diagnoses were hypertension with
intermittent atrial fibrillation, left ventricular hypertrophy,
pulmonary hypertension, visceral hypoperfusion, pyelo-
nephritis, an old portal venous thrombosis, fatty liver,
hyperuricemia and pulmonary embolism in 10/07. Many of
these diagnoses are pathogenetically related to the known
Rendu-Osler-Weber disease.
The patient reported that epistaxis first occurred in her
adolescence (at the age of 16 years), approximately one to
two times per week and self-limiting, but showed a clear
progression over the years.
Transfusions were given for the first time at the age of 40
years. At the age of 50 years epistaxis was not any more self-
limiting and occurred on average five times a week.
In the last four years she was therefore transfused
with more than one hundred erythrocyte concentrates and
had partly life-threatening haemoglobin levels. During this
period the haemoglobin levels were permanently low with
extreme values between 6.3 g/dL and 11.8 g/dL. Although the
patient has an arterial hypertension there seemed to be no
clear correlation between high blood pressures and severe
epistaxis attacks which can be deduced from an excellent
documentation by the patients’ husband.
The diagnosis Rendu-Osler-Weber disease was identified
in the 1980s with a strongly positive family history: her
father, two brothers and two of her three children also
showed/show symptoms of this illness.
Multiple endoscopic intranasal coagulations were per-
formed using neodymium, CO2 lasers, or bipolar coagu-
lation instruments. Failure in the control of the episodes
of massive epistaxis led to transarterial embolisation of
the maxillary, the facial and the sphenopalatine arteries
and attempts of septodermoplasty. Even these extended
procedures failed to prevent recurrence.
Two months after extensive neuroradiological emboli-
sation epistaxis was heavier than ever before and the
patient became almost entirely dependent on bilateral nasal
dressings, so all treatment modalities except radiotherapy
were exploited but had no permanent success.
Before we decided to perform an external radiotherapy
treatment it was discussed to employ brachytherapy. But as
merely contact to the nasal cavity caused heavy bleedings,
this modality was not considered as realistic option.
Radiotherapy planning was performed using the solution
commercialized by VARIAN with the Eclipse treatment
planning system (TPS) and the Clinac accelerator (Figures
1 and 2). The planning CT was carried out with 3mm
step size, positioning was done with a thermoplastic mask
system (Figure 3). Intensity-modulated radiotherapy was
performed to optimally spare the surrounding normal
tissues. Altogether we administered 50Gy in 2Gy single
fractions (5 days per week), the therapy lasted five weeks
without interruptions. This conventional dosing schedule
was chosen to avoid possible late complications concerning
the organs at risk, the end dose was specified empirically.
The nose was tamponaded before the beginning of
the radiotherapy, the tamponade was changed once during
the radiotherapy course. To prevent bacterial infections
causing sinusitis the patient was daily treated by antibiotics
(Aminopenicillin combined with clavulan acid p. o. twice a
day). Two weeks after the last radiation fraction the nasal
dressing could be removed without problems in the OR.
Endoscopical control did reveal an almost avascular white
mucosa without any trace of bleeding spots, previously
existing hemangiomas and crusts had disappeared. Only
on the dorso-apical edge of the vast septal perforation we
could detect a 3mm bluish spot as possible spot for an old
hemangioma (Figures 4 and 5).
3. Discussion
The rationale to treat HHT-related severe recurrent epistaxis
with radiotherapy is to irreversibly destroy fibrodysplastic
microvessels. The main mechanism as discussed in the
literature might be radiation-induced demise of endothelial
cells due to apoptosis. These cells are considered to be very
radiosensitive. The exact underlying molecular pathways of
endothelium dysfunction are not known so far [7, 8].
A bigger data set was acquired for intranasal brachyther-
apy for epistaxis in 43 patients with Rendu-Osler disease
treated between 1971–1991 at Henri Mondor Hospital. Dose
at one application ranged from 15–35Gy with a median
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Figure 2: Radiotherapy planning II. Another CT section at the lower PTV boundary. Small insets show the complete extension of the PTV.
Figure 3:Radiotherapy positioning. Positioning of the patient on the
couch. The thermoplastic mask system is used to prevent the patient
from moving during the treatment. The lines marked on the mask
system are used for the room lasers which are used to define the
exact positioning.
of 30Gy. The time to recurrence of significant epistaxis
ranged from 6–178 months with a median of 24 months.
The dose prescribed did not correlate with control rate. The
only brachytherapy complication was septal perforation in 4
patients; in one this was a result of repeated nasal coagulation
[6].
Pizzi et al. performed a similar but smaller study. The
dose given to the reference isodose was 30Gy. Complete
remission was seen in 4 patients. In 2 patients the response
has lasted 18 and 32months and 2 others had a shorter follow
Figure 4: Endoscopy of the right nasal cavity following removal
of the nasal dressing 2 weeks after the last radiotherapy showed a
vast septal perforation due to multiple endonasal interventions. A
3mmbluish spot at the dorso apical border of the septal perforation
and very fine teleangiectatic vessels were the only possible and now
inactive sites of the former extensive teleangiectatic lesions.
up. In 5 patients, a good response was obtained (mean: 58
months) [9].
Up to now, only very few trials or case reports are
reported on external irradiation [9–11].
Although a bigger data set is missing, external radiother-
apy seems to be an eﬀective treatment in this setting, but still
has to be used as a second line therapy as other treatment
modalities are faster and have potentially less side eﬀects.
But as a palliative treatment it may replace other treatment
methods, especially if they failed before [9].
4 Case Reports in Medicine
Figure 5: Endoscopic picture of the right nasal cavity with anemic
and white nasal mucosa.
Acknowledgment
Informed consent was obtained from the patient for publica-
tion of this case report and any accompanying images.
References
[1] B. Fernandez-Jorge, J. Del Pozo Losada, S. Paradela, C.
Martinez-Gonzalez, and E. Fonseca, “Treatment of cutaneous
and mucosal telangiectases in hereditary hemorrhagic telang-
iectasia: report of three cases,” Journal of Cosmetic and Laser
Therapy, vol. 9, no. 1, pp. 29–33, 2007.
[2] A. J. Juares, A. R. Dell’Aringa, J. C. Nardi, K. Kobari, V. L.
Gradim Moron Rodrigues, and R. M. Perches Filho, “Rendu-
Osler-Weber syndrome: case report and literature review,”
Brazilian Journal of Otorhinolaryngology, vol. 74, no. 3, pp.
452–457, 2008.
[3] L. Jovancevic and S. M. Mitrovic, “Epistaxis in patients with
hereditary hemorrhagic teleangiectasia,” Medicinski Pregled,
vol. 59, no. 9-10, pp. 443–449, 2006.
[4] C. M. Strother and T. H. Newton, “Percutaneous embolization
to control epistaxis in Rendu-Osler-Weber disease,” Archives of
Otolaryngology, vol. 102, no. 1, pp. 58–60, 1976.
[5] A. R. Harwood, J. C. Wojak, and R. Barry, “External beam
radiotherapy for severe epistaxis from Osler-Weber-Rendu
disease,” The Journal of the Louisiana State Medical Society, vol.
154, no. 3, pp. 154–155, 2002.
[6] S. Pohar, J. J. Mazeron, M. Ghilezan, J. P. Le Bourgeois, and B.
Pierquin, “Management of epistaxis in Rendu-Osler disease:
is brachytherapy eﬀective?” International Journal of Radiation
Oncology Biology Physics, vol. 27, no. 5, pp. 1073–1077, 1993.
[7] T. Girinsky, “Eﬀects of ionizing radiation on the blood vessel
wall,” Journal des Maladies Vasculaires, vol. 25, no. 5, pp. 321–
324, 2000.
[8] F. Milliat, A. Francois, R. Tamarat, and M. Benderitter, “Role
of endothelium in radiation-induced normal tissue damages,”
Annales de Cardiologie et d’Angeiologie, vol. 57, no. 3, pp. 139–
148, 2008.
[9] G. Pizzi, G. Turcato, R. Polico, M. Busetto, M. Antonello,
andM. Princivalli, “Brachytherapy of epistaxis in Rendu-Osler
disease. Indications, technic, results,” Radiologia Medica, vol.
89, no. 6, pp. 861–864, 1995.
[10] M. Esparcia Navarro, F. Ferrer Baixauli, S. Moya Albiol, et al.,
“Rendu-Osler disease. Follow-up of 6 patients treated by
embolization. Nasal telecobaltotherapy in a refractory case,”
Acta Otorrinolaringologica Espanola, vol. 50, no. 3, pp. 197–
201, 1999.
[11] A. Escalante, A. Pinzon, E. Belloso, A. Pozo, and C. Juan,
“Cobalt therapy in the treatment of Osler-Rendu disease.
Apropos of two cases,” Acta Otorrinolaringologica Espanola,
vol. 39, no. 1, pp. 57–59, 1988.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
